Piper Sandler Reaffirms Overweight Rating for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT)‘s stock had its “overweight” rating reaffirmed by equities researchers at Piper Sandler in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $118.00 price objective on the healthcare product maker’s stock, up from their prior price objective of $115.00. Piper Sandler’s target price suggests a potential upside of 17.17% from the stock’s previous close.

ABT has been the topic of a number of other research reports. Bank of America decreased their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. UBS Group dropped their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Oppenheimer reduced their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. BTIG Research raised their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.61.

Abbott Laboratories Trading Up 1.9%

Shares of ABT opened at $100.71 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market cap of $175.41 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.73 and a beta of 0.61. The stock has a fifty day moving average price of $89.89 and a two-hundred day moving average price of $102.17. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the business earned $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors have recently made changes to their positions in the stock. Nia Impact Advisors LLC raised its position in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. American National Bank of Texas boosted its holdings in shares of Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares in the last quarter. Park Place Capital Corp increased its stake in shares of Abbott Laboratories by 11.0% in the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after purchasing an additional 81 shares during the last quarter. Clayton Financial Group LLC raised its holdings in shares of Abbott Laboratories by 1.4% during the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock worth $779,000 after buying an additional 84 shares in the last quarter. Finally, Jamison Private Wealth Management Inc. lifted its position in shares of Abbott Laboratories by 0.5% during the 4th quarter. Jamison Private Wealth Management Inc. now owns 15,854 shares of the healthcare product maker’s stock worth $1,986,000 after buying an additional 85 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.